SARS-CoV-2 in Mexico: Beyond Detection Methods, Scope and Limitations

Diagnostics (Basel). 2021 Jan 14;11(1):124. doi: 10.3390/diagnostics11010124.

Abstract

The new coronavirus that was first identified in December 2019 in Wuhan China, now called SARS-CoV-2, which causes the disease called COVID-19, has spread from China to the entire world in a few months. Due to its contagious potential (R0: 5.7) and because there is still no effective treatment to stop the infection, and a vaccine for prevention it is not yet available to the general population, COVID-19 is currently considered a global health problem. The need to implement sensitive methods for the identification of individuals with COVID-19 has led to the development of different molecular and immunological tests. The importance of a timely and accurate diagnosis is essential to determine the course of the pandemic. The interpretation of the results obtained by each test as well as the factors that affect these results have not been fully described. In this review, we describe and analyze the different SARS-CoV-2 detection methods that have been performed in Mexico and are available worldwide, outlining their strengths and weaknesses. Further, a broader perspective of the correct use and interpretation of the results obtained with these diagnostic tools is proposed to improve the containment strategy and identify the true impact of the pandemic.

Keywords: CLIA; COVID-19; ELISA; IgG; IgM; SARS-CoV-2; antibodies; diagnostic test; immune host response; immunoassay; lateral flow assay; rapid test; viral detection.

Publication types

  • Review